Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (461)	1/3/2006 12:28:07 PM
From: Jibacoa	Respond to of 802

It is usually encouraging to start the new year with a positive move.<g> But it would probably be better to wait for the 4th Q results since on the 3rdQ the revenues were up 90% (0.41M vs. $0.21M) and the loss was cut from $0.26/shr to $$0.18/shr. however, the 4thQ results most probably won't show the same /shr improvement since in 2004 revenues were 1.2M and the loss $0.16/shr. The stock needs to hold the 5.25 level and be able to close above 5.80 before it can test its more important resistance above 6.20 <g> bigcharts.marketwatch.com Bernard

To: zeta1961 who wrote (461)	2/8/2006 12:26:42 PM
From: tuck	Read Replies (2) \| Respond to of 802

[Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer] >>Clinical Cancer Research Vol. 12, 878-887, February 2006 Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer Scott J. Antonia1,2, Noweeda Mirza1, Ingo Fricke1, Alberto Chiappori1,2, Patricia Thompson1, Nicholas Williams1, Gerold Bepler1,2, George Simon1,2, William Janssen1,2, Ji-Hyun Lee1, Kerstin Menander3, Sunil Chada3 and Dmitry I. Gabrilovich1,2 Authors' Affiliations: 1 H. Lee Moffitt Cancer Center and Research Institute, 2 Department of Interdisciplinary Oncology, University of South Florida, Tampa, Florida, and 3 Introgen Therapeutics, Houston, Texas Requests for reprints: Dmitry Gabrilovich, Department of Interdisciplinary Oncology, University of South Florida, MRC, Room 2067, 12902 Magnolia Drive, Tampa, FL 33612. Phone: 813-903-6863; Fax: 813-632-1328; E-mail: dgabril@moffitt.usf.edu. Purpose: The initial goal of this study was to test the immunologic and clinical effects of a new cancer vaccine consisting of dendritic cells (DC) transduced with the full-length wild-type p53 gene delivered via an adenoviral vector in patients with extensive stage small cell lung cancer. Experimental Design: Twenty-nine patients with extensive stage small cell lung cancer were vaccinated repeatedly at 2-week intervals. Most of the patients received three immunizations. p53-specific responses were evaluated, and phenotype and function of T cells, DCs, and immature myeloid cells were analyzed and correlated with antigen-specific immune responses. Objective clinical response to vaccination as well as subsequent chemotherapy was evaluated. Results: p53-specific T cell responses to vaccination were observed in 57.1% of patients. Immunologic responses to vaccination were positively associated with a moderate increase in the titer of antiadenovirus antibodies, and negatively with an accumulation of immature myeloid cells. One patient showed a clinical response to vaccination whereas most of the patients had disease progression. However, we observed a high rate of objective clinical responses to chemotherapy (61.9%) that immediately followed vaccination. Clinical response to subsequent chemotherapy was closely associated with induction of immunologic response to vaccination. Conclusions: This study provides clinical support for an emerging paradigm in cancer immunotherapy, wherein optimal use of vaccination might be more effective, not as a separate modality, but in direct combination with chemotherapy.<< Cheers, Tuck